WO2004035783A3 - Complexes proteiques de la voie de signalisation du facteur de necrose tumorale alpha - Google Patents

Complexes proteiques de la voie de signalisation du facteur de necrose tumorale alpha Download PDF

Info

Publication number
WO2004035783A3
WO2004035783A3 PCT/EP2003/050655 EP0350655W WO2004035783A3 WO 2004035783 A3 WO2004035783 A3 WO 2004035783A3 EP 0350655 W EP0350655 W EP 0350655W WO 2004035783 A3 WO2004035783 A3 WO 2004035783A3
Authority
WO
WIPO (PCT)
Prior art keywords
alpha
complexes
tnf
signalling pathway
tumor
Prior art date
Application number
PCT/EP2003/050655
Other languages
English (en)
Other versions
WO2004035783A9 (fr
WO2004035783A2 (fr
Inventor
Tewis Bouwmeester
Bettina Huhse
Angela Bauch
Heinz Ruffner
Andreas Bauer
Bernhard Kuester
Giulio Superti-Furga
Ulrich Kruse
Original Assignee
Cellzome Ag
Tewis Bouwmeester
Bettina Huhse
Angela Bauch
Heinz Ruffner
Andreas Bauer
Bernhard Kuester
Giulio Superti-Furga
Ulrich Kruse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20020021809 external-priority patent/EP1403282A1/fr
Application filed by Cellzome Ag, Tewis Bouwmeester, Bettina Huhse, Angela Bauch, Heinz Ruffner, Andreas Bauer, Bernhard Kuester, Giulio Superti-Furga, Ulrich Kruse filed Critical Cellzome Ag
Priority to AU2003298261A priority Critical patent/AU2003298261A1/en
Publication of WO2004035783A2 publication Critical patent/WO2004035783A2/fr
Publication of WO2004035783A9 publication Critical patent/WO2004035783A9/fr
Publication of WO2004035783A3 publication Critical patent/WO2004035783A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne les complexes protéiques de la voie de signalisation du facteur de nécrose tumorale alpha (TNF-α), les protéines composant ces complexes, les fragments et dérivés de ces protéines composant ces complexes, ainsi que les anticorps spécifiques aux complexes. La présente invention concerne également des procédés pour utiliser les complexes de la voie de signalisation de TNF-α et leur interaction dans le cadre, entre autres, d'un criblage, d'un diagnostic et d'un traitement, ainsi que des procédés pour préparer lesdits complexes. En outre, cette invention concerne des oligonucléotides de siARN qui ont un effet important sur l'expression des protéines des complexes selon cette invention.
PCT/EP2003/050655 2002-09-26 2003-09-24 Complexes proteiques de la voie de signalisation du facteur de necrose tumorale alpha WO2004035783A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003298261A AU2003298261A1 (en) 2002-09-26 2003-09-24 Protein complexes of the tumor-necrosis-factor-alpha (tnf-alpha) signalling pathway

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20020021809 EP1403282A1 (fr) 2002-09-26 2002-09-26 Complexes de protéines de la voie de signalisation du facteur de nécrose tumorale-alpha (TNF-alpha)
EP02021809.5 2002-09-26
EP03100274 2003-02-10
EP03100274.4 2003-05-07

Publications (3)

Publication Number Publication Date
WO2004035783A2 WO2004035783A2 (fr) 2004-04-29
WO2004035783A9 WO2004035783A9 (fr) 2004-09-30
WO2004035783A3 true WO2004035783A3 (fr) 2004-11-11

Family

ID=32109134

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/050655 WO2004035783A2 (fr) 2002-09-26 2003-09-24 Complexes proteiques de la voie de signalisation du facteur de necrose tumorale alpha

Country Status (2)

Country Link
AU (1) AU2003298261A1 (fr)
WO (1) WO2004035783A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1697407A2 (fr) * 2003-11-28 2006-09-06 Medical Research Council Regulation impliquant abin-2
CN101925612A (zh) * 2007-11-27 2010-12-22 维文蒂阿生物技术公司 针对癌相关的nfkbib变体的表位的抗体及其用途
EP3304084B1 (fr) 2015-06-08 2022-03-23 Arquer Diagnostics Limited Procédés et kits
JP6854246B2 (ja) 2015-06-08 2021-04-07 アーケア ダイアグノスティクス リミテッド 尿サンプルの分析方法
CN114878833A (zh) * 2021-07-01 2022-08-09 浙江大学 一种检测抗过氧化物还原酶-1-IgG抗体的试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044626A1 (fr) * 1998-03-05 1999-09-10 Tularik Inc. Suppresseurs des domaines de l'apoptose

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044626A1 (fr) * 1998-03-05 1999-09-10 Tularik Inc. Suppresseurs des domaines de l'apoptose

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DENG L ET AL: "Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 103, no. 2, 13 October 2000 (2000-10-13), pages 351 - 361, XP002232447, ISSN: 0092-8674 *
JIANG Y ET AL: "Prevention of constitutive TNF receptor 1 signaling by silencer of death domains", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 283, no. 5401, 22 January 1999 (1999-01-22), pages 543 - 546, XP002232446, ISSN: 0036-8075 *
LEE JUSTINE C ET AL: "DEDD regulates degradation of intermediate filaments during apoptosis", JOURNAL OF CELL BIOLOGY, vol. 158, no. 6, 16 September 2002 (2002-09-16), &, pages 1051 - 1066, XP002274488, ISSN: 0021-9525 *
LOCKSLEY R M ET AL: "THE TNF AND TNF RECEPTOR SUPERFAMILIES: INTEGRATING MAMMALIAN BIOLOGY", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 104, 23 February 2001 (2001-02-23), pages 487 - 501, XP002951130, ISSN: 0092-8674 *
SAKURAI HIROAKI ET AL: "Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 38, 19 September 2003 (2003-09-19), &, pages 36916 - 36923, XP002274489, ISSN: 0021-9258 *
VAN HUFFEL S ET AL: "Identification of a novel A20-binding inhibitor of nuclear factor-kappa B activation termed ABIN-2", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 276, no. 32, 10 August 2001 (2001-08-10), pages 30216 - 30223, XP002955138, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
AU2003298261A8 (en) 2004-05-04
WO2004035783A9 (fr) 2004-09-30
WO2004035783A2 (fr) 2004-04-29
AU2003298261A1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
WO2004009622A3 (fr) Complexes de proteiniques de reseaux cellulaires fondant le developpement du cancer et d'autres maladies
WO2003087831A3 (fr) Proteines impliquees dans le cancer du sein
AU2002305450A1 (en) Proteomimetic compounds and methods
AU2003271174A1 (en) Double specific antibodies substituting for functional protein
WO2004031400A3 (fr) Ligands diffusibles derives de l'amyloide beta (addl), substituts d'addl, molecules de liaison aux addl, et leurs utilisations
WO2005018424A3 (fr) Anticorps specifiques de la proteine amyloide fibrillaire et procedure permettant de detecter des depots de proteines amyloides fibrillaires
WO2004092215A3 (fr) Methodes therapeutiques utilisant des agents liants specifiques de l'angiopoietine-2 humaine
PT1641483E (pt) Proteínas de fusão
WO2003104437A3 (fr) Anticorps anti-addl et leurs utilisations
WO2004013180A3 (fr) Anticorps anti-alpha-fetoproteine immu31, proteines de fusion et procedes d'utilisation de ceux-ci
WO2006029219A3 (fr) Anticorps monoclonaux humains anti-ctla4 dans le traitement du cancer
WO2003057134A3 (fr) Agents de liaison specifiques de l'angiopoietine-2 humaine
GEP20105022B (en) Use of polypeptides of the cupredoxin family in cancer therapy
WO2003076592A3 (fr) Nouvelle methode d'administration et de synthese intracellulaire de molecules sirna
WO2004007743A3 (fr) Utilisation d'acides nucleiques cpg dans les maladies a prions
WO2007098198A3 (fr) Modulation de formation d'os
WO2004029072A3 (fr) Molecules interagissant avec prpsc et utilisations associees
WO2020172621A8 (fr) Anticorps anti-cd33 et leurs procédés d'utilisation pour traiter le cancer
WO2002062780A3 (fr) Nouveaux ligands de recepteurs thyroidiens
WO2004094476A3 (fr) Compositions et methodes se rapportant a stop-1
WO2004012673A3 (fr) Methodes et reactifs relatifs a l'inflammation et a l'apoptose
WO2004035783A3 (fr) Complexes proteiques de la voie de signalisation du facteur de necrose tumorale alpha
WO2004069860A3 (fr) Proteines conjuguees a isg15
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
WO2001007479A3 (fr) Matieres vivantes et methodes utiles pour le diagnostic ou le traitement de maladies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGE 1, DESCRIPTION, REPLACED BY A NEW PAGE 1

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP